Quantum BioPharma Ltd. (QNTM)
Every figure this model derived for QNTM, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust.
The figures, and where each came from
This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.
| Figure | Value | XBRL tag | As at |
|---|---|---|---|
| capex | 0 | PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
2024-12-31 |
| cash | 1,905,357 | CashAndCashEquivalents |
2025-12-31 |
| current assets | 6,478,353 | CurrentAssets |
2025-12-31 |
| current liabilities | 6,058,294 | CurrentLiabilities |
2025-12-31 |
| equity | 6,924,475 | EquityAttributableToOwnersOfParent |
2025-12-31 |
| interest expense | 158,063 | FinanceCosts |
2025-12-31 |
| ocf | -8,237,012 | CashFlowsFromUsedInOperatingActivities |
2025-12-31 |
| sbc | 2,945,502 | ExpenseFromSharebasedPaymentTransactionsWithEmployees |
2025-12-31 |
The ratios
The figures themselves rather than their scores — what somebody looking up QNTM on one particular measure came for.
| Ratio | Value |
|---|---|
| current ratio | 1.07 |
| current ratio reported | 1.07 |
| dilution pct | 86.43 |
| ev owner earnings | -2.08 |
| interest cover | -96.81 |
| roic | -191.29 |
Everything else this filing tags
308 more elements from QNTM's own XBRL that this model has no measure for, newest reading each, largest first. Nothing here is converted, added up or renamed — it is the filing's own element names and the filing's own numbers.
| Element | Newest | As of | Periods | Unit |
|---|---|---|---|---|
RetainedEarnings | -198,286,170 | 2025-12-31 | 26 | USD |
IssuedCapital | 150,470,325 | 2024-12-31 | 12 | USD |
NetDeferredTaxAssets | 117,523,670 | 2025-12-31 | 18 | USD |
IssuedCapital | 98,016,649 | 2019-12-31 | 4 | CAD |
RetainedEarnings | -78,518,005 | 2019-12-31 | 4 | CAD |
Assets | 57,447,463 | 2019-12-31 | 4 | CAD |
EquityAndLiabilities | 57,447,463 | 2019-12-31 | 4 | CAD |
ComprehensiveIncome | -52,125,876 | 2019-12-31 | 4 | CAD |
AccountingProfit | -52,013,186 | 2019-12-31 | 4 | CAD |
ProfitLoss | -52,013,186 | 2019-12-31 | 4 | CAD |
Equity | 48,222,087 | 2019-12-31 | 6 | CAD |
WeightedAverageShares | 38,732,381 | 2022-12-31 | 3 | shares |
ProfitLossFromOperatingActivities | -36,669,996 | 2019-12-31 | 4 | CAD |
SharePremium | 35,405,812 | 2025-12-31 | 26 | USD |
ExpenseByNature | 34,262,996 | 2019-12-31 | 4 | CAD |
DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised | 32,754,253 | 2019-12-31 | 4 | CAD |
ExpenseByNature | 27,429,611 | 2022-12-31 | 8 | USD |
ComprehensiveIncome | -26,956,840 | 2025-12-31 | 28 | USD |
ProfitLossFromContinuingOperations | -26,956,840 | 2025-12-31 | 30 | USD |
ProfitLossAttributableToNoncontrollingInterests | -26,956,840 | 2025-12-31 | 30 | USD |
OtherComprehensiveIncome | -26,916,102 | 2025-12-31 | 26 | USD |
ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects | -26,175,286 | 2025-12-31 | 26 | USD |
ProfitLoss | -23,253,808 | 2025-09-30 | 24 | USD |
SharePremium | 23,091,099 | 2019-12-31 | 4 | CAD |
IntangibleAssetsOtherThanGoodwill | 22,358,932 | 2019-12-31 | 4 | CAD |
CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners | 17,850,174 | 2022-12-31 | 7 | USD |
KeyManagementPersonnelCompensation | 17,312,577 | 2019-12-31 | 4 | CAD |
ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations | 16,400,000 | 2022-12-31 | 2 | CAD |
AdjustmentsForSharebasedPayments | 16,061,319 | 2019-12-31 | 4 | CAD |
IncreaseDecreaseThroughSharebasedPaymentTransactions | 16,061,319 | 2019-12-31 | 4 | CAD |
ProfitLossFromOperatingActivities | -15,302,374 | 2025-12-31 | 25 | USD |
OperatingExpense | 15,302,374 | 2025-12-31 | 30 | USD |
AccountingProfit | -14,915,529 | 2024-12-31 | 15 | USD |
GeneralAndAdministrativeExpense | 14,811,529 | 2019-12-31 | 4 | CAD |
TaxExpenseIncomeAtApplicableTaxRate | -13,783,494 | 2019-12-31 | 4 | CAD |
IncreaseDecreaseInCashAndCashEquivalents | -13,202,193 | 2019-12-31 | 4 | CAD |
ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations | 12,730,942 | 2022-12-31 | 1 | USD |
KeyManagementPersonnelCompensationSharebasedPayment | 12,476,385 | 2019-12-31 | 4 | CAD |
GainsLossesOnChangeInFairValueOfDerivatives | -11,909,532 | 2025-12-31 | 38 | USD |
PropertyPlantAndEquipment | 11,804,145 | 2019-12-31 | 4 | CAD |
NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | 11,780,864 | 2019-12-31 | 4 | CAD |
AdjustmentsForFairValueGainsLosses | 11,669,157 | 2019-12-31 | 4 | CAD |
CashFlowsFromUsedInFinancingActivitiesContinuingOperations | 11,618,870 | 2024-12-31 | 17 | USD |
IssueOfEquity | 11,539,417 | 2019-12-31 | 4 | CAD |
Assets | 11,160,909 | 2025-12-31 | 26 | USD |
EquityAndLiabilities | 11,160,909 | 2025-12-31 | 26 | USD |
LeasesAsLesseeRelatedPartyTransactions | 9,612,409 | 2024-09-30 | 3 | USD |
GeneralAndAdministrativeExpense | 9,410,097 | 2024-12-31 | 25 | USD |
Liabilities | 9,225,376 | 2019-12-31 | 4 | CAD |
SellingGeneralAndAdministrativeExpense | 9,047,918 | 2025-12-31 | 13 | USD |
ProfitLossAttributableToOwnersOfParent | -8,842,461 | 2024-09-30 | 4 | USD |
PurchaseOfInvestmentProperty | 7,999,991 | 2018-12-31 | 2 | CAD |
TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss | 7,797,290 | 2019-12-31 | 4 | CAD |
NoncurrentTradeReceivables | 7,431,656 | 2022-12-31 | 2 | USD |
IncreaseDecreaseThroughAcquisitionOfSubsidiary | 7,290,731 | 2021-12-31 | 2 | USD |
AcquisitiondateFairValueOfTotalConsiderationTransferred | 7,290,731 | 2023-12-31 | 1 | USD |
TaxExpenseIncomeAtApplicableTaxRate | -7,143,560 | 2025-12-31 | 18 | USD |
CashFlowsFromUsedInOperatingActivitiesContinuingOperations | -6,876,479 | 2024-12-31 | 17 | USD |
ShareIssueRelatedCost | 6,634,405 | 2018-12-31 | 2 | CAD |
IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate | 6,186,251 | 2023-12-31 | 1 | USD |
CashFlowsFromUsedInFinancingActivities | 6,098,966 | 2025-12-31 | 30 | USD |
Liabilities | 6,058,294 | 2025-12-31 | 26 | USD |
PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | 6,000,000 | 2019-12-31 | 2 | CAD |
CashFlowsFromUsedInFinancingActivities | 5,332,454 | 2019-12-31 | 4 | CAD |
ChangesInIntangibleAssetsOtherThanGoodwill | 5,145,932 | 2024-06-30 | 5 | USD |
Equity | 5,102,615 | 2025-12-31 | 46 | USD |
KeyManagementPersonnelCompensationShorttermEmployeeBenefits | 4,836,192 | 2019-12-31 | 4 | CAD |
ProceedsFromIssuingShares | 4,593,777 | 2019-12-31 | 4 | CAD |
IntangibleAssetsOtherThanGoodwill | 4,513,207 | 2025-12-31 | 25 | USD |
TradeAndOtherCurrentPayables | 4,467,826 | 2019-12-31 | 4 | CAD |
TradeAndOtherPayables | 4,362,068 | 2024-12-31 | 10 | USD |
AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables | 4,270,397 | 2024-12-31 | 21 | USD |
GainsOnDisposalsOfPropertyPlantAndEquipment | 4,249,582 | 2022-12-31 | 1 | USD |
TradeAndOtherCurrentPayables | 4,182,083 | 2025-12-31 | 26 | USD |
IncreaseDecreaseInCashAndCashEquivalents | -4,090,515 | 2025-12-31 | 15 | USD |
AmortisationIntangibleAssetsOtherThanGoodwill | 3,894,467 | 2020-12-31 | 2 | USD |
ProfessionalFeesExpense | 3,730,556 | 2019-12-31 | 4 | CAD |
AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives | -3,568,305 | 2019-12-31 | 2 | CAD |
LossesOnChangeInFairValueOfDerivatives | 3,568,305 | 2019-12-31 | 2 | CAD |
KeyManagementPersonnelCompensation | 3,495,938 | 2025-12-31 | 38 | USD |
ProfessionalFeesExpense | 3,278,735 | 2025-12-31 | 38 | USD |
ProceedsFromIssueOfBondsNotesAndDebentures | 3,243,165 | 2025-12-31 | 9 | USD |
AdjustmentsForDepreciationAndAmortisationExpense | 3,146,680 | 2019-12-31 | 4 | CAD |
DepreciationAndAmortisationExpense | 3,146,680 | 2019-12-31 | 4 | CAD |
AdjustmentsForSharebasedPayments | 2,945,502 | 2025-12-31 | 20 | USD |
IncreaseDecreaseThroughSharebasedPaymentTransactions | 2,945,502 | 2025-12-31 | 20 | USD |
ResearchAndDevelopmentExpense | 2,763,174 | 2025-12-31 | 37 | USD |
CurrentDerivativeFinancialLiabilities | 2,646,269 | 2019-12-31 | 2 | CAD |
ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities | 2,500,425 | 2025-12-31 | 3 | USD |
AdjustmentsForProvisions | -2,477,559 | 2025-03-31 | 15 | USD |
IssueOfConvertibleInstruments | 2,420,000 | 2025-03-28 | 16 | CAD |
GrossProfit | -2,407,000 | 2019-12-31 | 2 | CAD |
LossesOnLitigationSettlements | 2,350,000 | 2025-12-31 | 5 | USD |
WagesAndSalaries | 2,267,308 | 2019-12-31 | 4 | CAD |
WagesAndSalaries | 2,204,319 | 2025-12-31 | 38 | USD |
AccrualsClassifiedAsCurrent | 2,200,232 | 2025-12-31 | 22 | USD |
AdministrativeExpense | 2,172,824 | 2019-12-31 | 4 | CAD |
ProceedsFromBorrowingsClassifiedAsFinancingActivities | 2,113,386 | 2025-12-31 | 13 | USD |
TradeAndOtherCurrentReceivables | 2,070,055 | 2019-12-31 | 4 | CAD |
TradeAndOtherReceivables | 2,070,055 | 2019-12-31 | 4 | CAD |
IssueOfConvertibleInstruments | 2,000,000 | 2025-12-31 | 21 | USD |
KeyManagementPersonnelCompensationSharebasedPayment | 1,994,558 | 2025-12-31 | 38 | USD |
TradeAndOtherCurrentPayablesToTradeSuppliers | 1,981,851 | 2025-12-31 | 22 | USD |
CostOfSales | 1,959,111 | 2019-12-31 | 2 | CAD |
CashFlowsFromUsedInInvestingActivities | -1,952,469 | 2025-12-31 | 30 | USD |
OtherIncome | 1,946,491 | 2025-12-31 | 24 | USD |
CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued | 1,908,412 | 2019-12-31 | 2 | CAD |
NoncontrollingInterests | -1,821,860 | 2025-12-31 | 21 | USD |
GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss | -1,692,842 | 2024-12-31 | 19 | USD |
CashFlowsFromUsedInInvestingActivitiesContinuingOperations | -1,503,559 | 2024-12-31 | 17 | USD |
KeyManagementPersonnelCompensationShorttermEmployeeBenefits | 1,501,380 | 2025-12-31 | 38 | USD |
AdjustmentsForFinanceIncome | -1,491,001 | 2025-12-31 | 25 | USD |
IncreaseDecreaseThroughExerciseOfWarrantsEquity | 1,372,763 | 2023-12-31 | 3 | USD |
OtherExpenseByNature | 1,330,043 | 2023-09-30 | 2 | USD |
InventoryWritedown2011 | 1,315,941 | 2019-12-31 | 2 | CAD |
Borrowings | 1,300,549 | 2025-12-31 | 8 | USD |
AdditionsFromPurchasesBiologicalAssets | 1,297,734 | 2019-12-31 | 2 | CAD |
DeferredTaxAssets | 1,242,040 | 2025-12-31 | 1 | USD |
DeferredTaxLiabilities | 1,242,040 | 2025-12-31 | 1 | USD |
ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | 1,181,499 | 2025-12-31 | 19 | USD |
AdjustmentsForIncreaseDecreaseInTradeAccountPayable | 1,178,497 | 2025-12-31 | 9 | USD |
AdjustedWeightedAverageShares | 1,136,922 | 2024-12-31 | 29 | shares |
AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables | -1,079,067 | 2019-12-31 | 4 | CAD |
IssuedCapitalOrdinaryShares | 1,028,780 | 2025-09-30 | 8 | USD |
NumberOfSharesIssued | 1,000,000 | 2023-12-31 | 1 | shares |
AdjustmentsForDecreaseIncreaseInInventories | -942,939 | 2019-12-31 | 2 | CAD |
Inventories | 942,939 | 2019-12-31 | 2 | CAD |
AdjustmentsForUnrealisedForeignExchangeLossesGains | 934,100 | 2022-12-31 | 7 | USD |
RepairsAndMaintenanceExpense | 924,945 | 2019-12-31 | 4 | CAD |
AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables | 825,120 | 2019-12-31 | 4 | CAD |
RepaymentsOfCurrentBorrowings | 800,000 | 2025-12-31 | 3 | CAD |
ComprehensiveIncomeAttributableToNoncontrollingInterests | -781,554 | 2025-12-31 | 26 | USD |
CashAndCashEquivalentsRecognisedAsOfAcquisitionDate | 768,964 | 2023-12-31 | 1 | USD |
IncreaseDecreaseThroughExerciseOfOptions | 732,598 | 2019-12-31 | 4 | CAD |
ProceedsFromExerciseOfOptions | 732,598 | 2019-12-31 | 4 | CAD |
AdjustmentsForDecreaseIncreaseInBiologicalAssets | -682,739 | 2019-12-31 | 2 | CAD |
AdjustmentsForGainsLossesOnChangeInFairValueLessCostsToSellBiologicalAssets | -682,739 | 2019-12-31 | 2 | CAD |
GainsLossesOnFairValueAdjustmentAttributableToPhysicalChangesBiologicalAssets | 682,739 | 2019-12-31 | 2 | CAD |
IncreaseDecreaseThroughTransfersAndOtherChangesBiologicalAssets | 682,739 | 2019-12-31 | 2 | CAD |
OtherPayables | 619,029 | 2024-12-31 | 10 | USD |
SellingExpense | 616,002 | 2022-12-31 | 1 | USD |
DecreaseDueToHarvestBiologicalAssets | 614,995 | 2019-12-31 | 2 | CAD |
ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | 614,520 | 2019-12-31 | 2 | CAD |
AdjustmentsForDepreciationAndAmortisationExpense | 545,780 | 2025-12-31 | 28 | USD |
DepreciationAndAmortisationExpense | 545,780 | 2025-12-31 | 38 | USD |
AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives | 521,809 | 2022-12-31 | 8 | USD |
InterestIncomeOnLoansAndReceivables | 513,925 | 2024-12-31 | 4 | USD |
CurrentDebtInstrumentsIssued | 472,497 | 2025-12-31 | 8 | USD |
PurchaseOfInvestmentProperty | 462,325 | 2025-12-31 | 26 | USD |
PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | 462,325 | 2025-12-31 | 13 | USD |
ProceedsFromSalesOfInvestmentProperty | 460,508 | 2025-12-31 | 20 | USD |
CurrentInvestments | 459,080 | 2025-12-31 | 22 | USD |
InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | 459,080 | 2025-12-31 | 28 | USD |
LongtermDeposits | 459,080 | 2025-12-31 | 5 | USD |
CurrentPrepaidExpenses | 430,381 | 2019-12-31 | 4 | CAD |
PaymentsForDebtIssueCosts | 400,000 | 2024-12-31 | 3 | CAD |
RevenueFromInterest | 397,939 | 2024-09-30 | 5 | USD |
IssueOfEquity | 391,383 | 2025-12-31 | 16 | USD |
PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities | 389,640 | 2019-12-31 | 2 | CAD |
TradeAndOtherCurrentReceivables | 374,377 | 2022-12-31 | 8 | USD |
GainsLossesOnExchangeDifferencesOnTranslationNetOfTax | -366,546 | 2024-12-31 | 17 | USD |
ProceedsFromIssuingShares | 338,331 | 2025-12-31 | 30 | USD |
GrossLoanCommitments | 315,528 | 2018-12-31 | 2 | CAD |
CashFlowsFromUsedInInvestingActivities | -306,909 | 2019-12-31 | 4 | CAD |
CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued | 300,549 | 2022-12-31 | 7 | USD |
FeeAndCommissionExpense | 288,373 | 2024-09-30 | 2 | USD |
GainsOnDisposalsOfInvestments | 285,314 | 2025-12-31 | 2 | USD |
DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares | 258,588 | 2025-12-31 | 34 | shares |
Revenue | 257,099 | 2019-12-31 | 2 | CAD |
AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss | 243,468 | 2019-12-31 | 2 | CAD |
InterestRevenueExpense | 236,084 | 2025-12-31 | 33 | USD |
AdjustmentsForFairValueGainsLosses | 234,226 | 2022-12-31 | 8 | USD |
OtherReceivables | 231,053 | 2025-12-31 | 25 | USD |
TradeAndOtherReceivables | 231,053 | 2025-12-31 | 25 | USD |
LeaseLiabilities | 215,874 | 2022-12-31 | 10 | USD |
WarrantLiability | 212,002 | 2024-12-31 | 10 | USD |
AdjustmentsForInterestExpense | 206,454 | 2019-12-31 | 2 | CAD |
DirectorsRemunerationExpense | 203,521 | 2019-12-31 | 4 | CAD |
LeaseLiabilities | 202,869 | 2019-12-31 | 4 | CAD |
AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables | 196,677 | 2025-12-31 | 30 | USD |
NetForeignExchangeLoss | 186,959 | 2020-12-31 | 2 | USD |
ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment | 175,824 | 2019-12-31 | 2 | CAD |
AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets | -175,194 | 2025-12-31 | 3 | USD |
GainsLossesOnDisposalsOfInvestments | 175,194 | 2025-12-31 | 3 | USD |
CurrentAssetsRecognisedAsOfAcquisitionDate | 167,776 | 2023-12-31 | 1 | USD |
NumberOfOutstandingShareOptions | 160,956 | 2025-12-31 | 16 | pure |
NumberOfShareOptionsExercisableInSharebasedPaymentArrangement | 160,956 | 2025-12-31 | 9 | pure |
NumberOfShareOptionsGrantedInSharebasedPaymentArrangement | 155,692 | 2025-12-31 | 9 | pure |
ProceedsFromExerciseOfOptions | 148,086 | 2025-12-31 | 21 | USD |
NoncurrentLeaseLiabilities | 146,662 | 2019-12-31 | 2 | CAD |
CashOutflowForLeases | 143,071 | 2022-12-31 | 7 | USD |
DepreciationBiologicalAssets | 131,955 | 2019-12-31 | 2 | CAD |
RightofuseAssets | 127,410 | 2019-12-31 | 6 | CAD |
OtherIncome | 125,536 | 2019-12-31 | 4 | CAD |
LossesOnChangeInFairValueOfDerivatives | 117,136 | 2025-12-31 | 20 | USD |
DepreciationRightofuseAssets | 114,907 | 2022-12-31 | 6 | USD |
PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities | 113,862 | 2025-12-31 | 30 | USD |
OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation | -112,690 | 2019-12-31 | 2 | CAD |
ReserveOfExchangeDifferencesOnTranslation | -112,690 | 2019-12-31 | 2 | CAD |
TradeAndOtherPayablesRecognisedAsOfAcquisitionDate | 103,824 | 2023-12-31 | 1 | USD |
CurrentLeaseLiabilities | 103,165 | 2025-12-31 | 26 | USD |
ValueAddedTaxReceivables | 102,714 | 2025-12-31 | 12 | USD |
ExercisePriceShareOptionsGranted2019 | 102,563 | 2024-06-30 | 2 | USD/shares |
RightofuseAssets | 102,320 | 2025-12-31 | 28 | USD |
AdditionsToRightofuseAssets | 98,648 | 2022-12-31 | 3 | USD |
IncreaseDecreaseThroughExerciseOfWarrantsEquity | 94,991 | 2019-12-31 | 4 | CAD |
ReserveOfExchangeDifferencesOnTranslation | 91,533 | 2025-12-31 | 25 | USD |
AdjustmentsForDecreaseIncreaseInOtherCurrentAssets | 86,377 | 2024-12-31 | 13 | USD |
GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss | 84,568 | 2019-12-31 | 4 | CAD |
IssuedCapitalPreferenceShares | 84,358 | 2025-12-31 | 4 | USD |
InterestReceivable | 73,575 | 2025-12-31 | 18 | USD |
TradeReceivables | 70,478 | 2024-09-30 | 2 | USD |
PropertyPlantAndEquipment | 67,029 | 2025-12-31 | 24 | USD |
AdjustmentsForInterestExpense | 65,734 | 2025-12-31 | 16 | USD |
AdjustmentsForDecreaseIncreaseInInventories | 65,109 | 2025-12-31 | 9 | USD |
NetForeignExchangeGain | 62,385 | 2020-12-31 | 2 | USD |
CashOutflowForLeases | 56,207 | 2019-12-31 | 2 | CAD |
CurrentLeaseLiabilities | 56,207 | 2019-12-31 | 2 | CAD |
PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities | 56,207 | 2019-12-31 | 2 | CAD |
RawMaterials | 55,568 | 2025-09-30 | 3 | USD |
AdjustmentsForDecreaseIncreaseInPrepaidExpenses | 53,746 | 2025-12-31 | 9 | USD |
Inventories | 52,133 | 2025-12-31 | 15 | USD |
DepreciationRightofuseAssets | 48,764 | 2019-12-31 | 2 | CAD |
ProceedsFromExerciseOfWarrants | 43,257 | 2025-12-31 | 10 | USD |
ProceedsFromIssuingOtherEquityInstruments | 43,257 | 2025-12-31 | 3 | USD |
NumberOfInstrumentsOtherEquityInstrumentsGranted | 41,036 | 2024-12-31 | 9 | pure |
OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation | 40,738 | 2025-12-31 | 21 | USD |
NumberOfShareOptionsExercisedInSharebasedPaymentArrangement | 37,192 | 2025-12-31 | 7 | pure |
NumberOfShareOptionsExercisedInSharebasedPaymentArrangement | 37,192 | 2025-12-31 | 6 | options |
RawMaterialsAndConsumablesUsed | 33,827 | 2025-12-31 | 5 | USD |
PaymentsForShareIssueCosts | 32,705 | 2019-12-31 | 4 | CAD |
NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement | 32,690 | 2024-12-31 | 11 | pure |
DirectorsRemunerationExpense | 29,587 | 2025-03-31 | 3 | USD |
OtherReceivables | 23,530 | 2019-12-31 | 4 | CAD |
FinishedGoods | 22,054 | 2025-09-30 | 3 | USD |
InterestExpenseOnLeaseLiabilities | 19,062 | 2022-12-31 | 7 | USD |
ChangesInInventoriesOfFinishedGoodsAndWorkInProgress | 18,306 | 2025-12-31 | 5 | USD |
CurrentPrepaidExpenses | 15,290 | 2025-12-31 | 26 | USD |
InterestExpenseOnLeaseLiabilities | 15,258 | 2019-12-31 | 2 | CAD |
NumberOfShareOptionsExpiredInSharebasedPaymentArrangement | 12,500 | 2025-03-31 | 6 | pure |
WarrantReserve | 10,009 | 2025-12-31 | 18 | USD |
InterestExpense | 9,343 | 2024-12-31 | 14 | USD |
DividendsPaidToNoncontrollingInterests | 8,673 | 2023-12-31 | 3 | USD |
GainsOnLitigationSettlements | 5,156 | 2024-09-30 | 2 | USD |
OtherCurrentReceivables | 4,874 | 2024-09-30 | 2 | USD |
NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement | 1,900 | 2023-12-31 | 1 | pure |
ForeignExchangeLoss | -1,039 | 2025-12-31 | 12 | USD |
WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019 | 353 | 2024-09-30 | 2 | CAD/shares |
WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019 | 136 | 2023-12-31 | 1 | USD/shares |
WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 | 19 | 2025-12-31 | 9 | USD/shares |
WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 | 19 | 2025-09-30 | 8 | CAD/shares |
WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 | 19 | 2025-12-31 | 5 | USD/shares |
WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 | 19 | 2025-09-30 | 4 | CAD/shares |
WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 | 19 | 2025-12-31 | 5 | USD/shares |
WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 | 19 | 2025-09-30 | 4 | CAD/shares |
BasicEarningsLossPerShareFromContinuingOperations | -8 | 2025-12-31 | 19 | USD/shares |
DilutedEarningsLossPerShareFromContinuingOperations | -8 | 2025-12-31 | 16 | USD/shares |
BasicAndDilutedEarningsLossPerShare | -7 | 2019-12-31 | 4 | CAD/shares |
WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 | 6 | 2025-09-30 | 4 | CAD/shares |
WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 | 6 | 2025-12-31 | 2 | USD/shares |
WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019 | 5 | 2025-03-31 | 4 | USD/shares |
ParValuePerShare | 4 | 2024-09-06 | 5 | USD/shares |
BasicAndDilutedEarningsLossPerShareFromContinuingOperations | -2 | 2020-12-31 | 2 | USD/shares |
ProportionOfVotingPowerHeldInSubsidiary | 1 | 2025-12-31 | 2 | pure |
ParValuePerShare | 0 | 2025-07-21 | 3 | CAD/shares |
PercentageOfVotingEquityInterestsAcquired | 0 | 2023-07-31 | 7 | pure |
BasicAndDilutedEarningsLossPerShareFromDiscontinuedOperations | -0 | 2020-12-31 | 2 | USD/shares |
ApplicableTaxRate | 0 | 2025-12-31 | 22 | pure |
ProportionOfOwnershipInterestsHeldByNoncontrollingInterests | 0 | 2025-12-31 | 14 | pure |
ProportionOfVotingPowerHeldInAssociate | 0 | 2025-12-31 | 2 | pure |
DilutedEarningsLossPerShareFromDiscontinuedOperations | 0 | 2022-12-31 | 3 | USD/shares |
BorrowingsInterestRate | 0 | 2023-12-31 | 5 | pure |
GainsLossesOnFairValueAdjustmentInvestmentProperty | 0 | 2025-11-30 | 1 | USD |
GainsLossesOnFairValueAdjustmentInvestmentProperty | 0 | 2025-11-30 | 1 | CAD |
AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss | 0 | 2022-12-31 | 8 | USD |
BiologicalAssets | 0 | 2019-12-31 | 4 | CAD |
CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations | 0 | 2022-12-31 | 8 | USD |
CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations | 0 | 2024-12-31 | 17 | USD |
CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations | 0 | 2024-12-31 | 17 | USD |
CurrentBiologicalAssets | 0 | 2019-12-31 | 4 | CAD |
CurrentDerivativeFinancialLiabilities | 0 | 2025-12-31 | 11 | USD |
DeferredTaxExpenseIncome | 0 | 2019-12-31 | 4 | CAD |
DeferredTaxExpenseIncome | 0 | 2023-12-31 | 9 | USD |
IncreaseDecreaseThroughExerciseOfOptions | 0 | 2024-12-31 | 15 | USD |
NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners | 0 | 2022-12-31 | 6 | USD |
NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | 0 | 2025-12-31 | 21 | USD |
NoncurrentLeaseLiabilities | 0 | 2023-12-31 | 10 | USD |
ProfitLossFromDiscontinuedOperations | 0 | 2024-12-31 | 17 | USD |
PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities | 0 | 2024-12-31 | 16 | USD |
RepaymentsOfBondsNotesAndDebentures | 0 | 2023-12-31 | 11 | USD |
ShareIssueRelatedCost | 0 | 2025-12-31 | 14 | USD |
TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss | 0 | 2025-12-31 | 18 | USD |
TaxEffectOfForeignTaxRates | 0 | 2025-12-31 | 18 | USD |
BasicEarningsLossPerShareFromDiscontinuedOperations | 0 | 2024-12-31 | 15 | USD/shares |
OtherCurrentPayables | 0 | 2022-12-31 | 4 | USD |
AllowanceAccountForCreditLossesOfFinancialAssets | 0 | 2024-12-31 | 6 | USD |
NetInvestmentInFinanceLease | 0 | 2023-12-31 | 4 | USD |
TaxEffectFromChangeInTaxRate | 0 | 2025-12-31 | 14 | USD |
AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination | 0 | 2023-12-31 | 3 | USD |
ConsiderationPaidReceived | 0 | 2025-12-31 | 16 | USD |
CurrentFinanceLeaseReceivables | 0 | 2025-12-31 | 18 | USD |
GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss | 0 | 2024-12-31 | 17 | USD |
ImpairmentLoss | 0 | 2025-12-31 | 20 | USD |
NoncurrentFinanceLeaseReceivables | 0 | 2025-12-31 | 14 | USD |
CurrentDeferredIncomeOtherThanCurrentContractLiabilities | 0 | 2025-12-31 | 8 | USD |
CurrentWarrantLiability | 0 | 2025-12-31 | 8 | USD |
LoansAndAdvancesAtAmortisedCostAllowanceForExpectedCreditLosses | 0 | 2025-12-31 | 2 | USD |
NetDeferredTaxLiabilities | 0 | 2025-12-31 | 1 | USD |
What to be careful about
What this model itself distrusts about QNTM's figures. Written by the derivation as it ran, not added afterwards.
- no revenue found in XBRL
- analyst estimate not used: trailing EPS is not positive, so a growth rate would be meaningless
- quality DROPPED from the total: only 1 of 5 inputs could be computed (operating margin, sbc discipline, owner earnings, cash operating margin not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
- valuation rests on 1 of 2 inputs; not tagged: ev sales
- durability DROPPED from the total: only 0 of 4 inputs could be computed (worst year, contracted coverage, gross margin stability, cash flow stability not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
- growth DROPPED from the total: only 0 of 4 inputs could be computed (revenue growth, sustained growth, margin trend, margin recent not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
- 3 of 5 dimensions could not be measured (quality, durability, growth -- 60% of the model), so this row is not comparable with the others; its total rests on what was left